RealWorld Dynamix™: Biologic/JAK Switching in IBD US 2018 Spotlight
Data from Spherix’s third annual RealWorld Dynamix™: Biologic/JAK Switching in IBD (US) analyzed the charts of more than 1,000 IBD patients recently switched from one biologic/JAK to another. The audit captures data trended back to 2016 and can aid in assessing the evolution of this opportunity-laden market segment, which is critical for brands competing in the space, as well as those with aims to enter it.
The 2018 study captures details on switching patterns and patient types for all major brands competing in the Crohn’s disease and ulcerative colitis (UC) markets and offers the first glimpse of the impact that the first oral JAK inhibitor (Pfizer’s Xeljanz) has had on the market. View complimentary data highlights full 2018 report below.
Contact [email protected] for more information about the highlighted report or to see if your company already has access.
All company, brand or product names and logos in this document are trademarks of their respective holders.